Author response for "COVID‐19 vaccine effectiveness against hospitalization due to SARS‐CoV‐2: A test‐negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain"
Clara Mazagatos(Instituto de Salud Carlos III), The SARI surveillance VE group in Spain, Socorro Fernández‐Arribas(Junta de Castilla y León), Jesús Oliva(Instituto de Salud Carlos III), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Francisco del Pozo, Eva Martínez Ochoa(Gobierno de La Rioja), Susana Monge(Instituto de Salud Carlos III), Silvia Martínez‐Cuenca(Gobierno de Aragón), Bartolomé Sastre‐Palou(Conselleria de Sanitat Universal i Salut Pública), Luca Basile(Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública), Ana Gandarillas(Directorate General of Traffic), Virtudes Gallardo‐García(Junta de Andalucía), Concepción Delgado‐Sanz(Instituto de Salud Carlos III), Amparo Larrauri(Instituto de Salud Carlos III), Carmen Quiñones‐Rubio(Gobierno de La Rioja), Miriam García‐Vázquez(Gobierno de Aragón), Ana García‐Fulgueiras(Centre for Biomedical Network Research on Rare Diseases), Amelia Fernández‐Sierra(Hospital Universitario Virgen de las Nieves), Mar Rodríguez‐del Águila(Hospital Universitario Virgen de las Nieves), María Isabel Barranco‐Boada(Servicio Murciano de Salud), Ana Milagro(Hospital Universitario Miguel Servet), Olga Hidalgo‐Pardo(Conselleria de Sanitat Universal i Salut Pública), Isabel Losada‐Castillo(Xunta de Galicia), Nicola Lorusso, Miriam Latorre, Cristina Ruiz‐Sopeña(Junta de Castilla y León), María Ordobás, Olalla Vázquez-Cancela(Complejo Hospitalario Universitario de Santiago)
Cited by 0
Related Papers
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
|Eurosurveillance|2020|715
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334